This information is not collected centrally.<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"} } , "answeringMemberConstituency" : {"_value" : "Battersea"} , "answeringMemberPrinted" : {"_value" : "Jane Ellison"} , "dateOfAnswer" : {"_value" : "2015-03-26", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2015-03-26T11:24:54.81Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2015-03-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "IVF"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, how much was spent by his Department on the provision of in-vitro fertilisation in each year since 2010.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4036", "label" : {"_value" : "Biography information for Luciana Berger"} } , "tablingMemberConstituency" : {"_value" : "Liverpool, Wavertree"} , "tablingMemberPrinted" : [{"_value" : "Luciana Berger"} ], "uin" : "228777"} , {"_about" : "http://data.parliament.uk/resources/226704", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/226704/answer", "answerText" : {"_value" : "
NHS England has made no assessment of the factors contributing to the difference between 22,340 National Health Service-funded cycles of in vitro fertilisation in 2013 and 22,238 cycles in 2014, a reduction of less than 0.5%.<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"} } , "answeringMemberConstituency" : {"_value" : "Battersea"} , "answeringMemberPrinted" : {"_value" : "Jane Ellison"} , "dateOfAnswer" : {"_value" : "2015-03-16", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2015-03-16T17:46:12.123Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2015-03-11", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "IVF"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, pursuant to the Answer of 25 February 2015 to Question 224828, what assessment he has made of the factors contributing to the reduction in NHS-funded IVF cycles from 2013 to 2014.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4036", "label" : {"_value" : "Biography information for Luciana Berger"} } , "tablingMemberConstituency" : {"_value" : "Liverpool, Wavertree"} , "tablingMemberPrinted" : [{"_value" : "Luciana Berger"} ], "uin" : "227135"} , {"_about" : "http://data.parliament.uk/resources/226825", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/226825/answer", "answerText" : {"_value" : "
The Human Fertilisation and Embryology Authority (HFEA) is the United Kingdom\u2019s national regulator and will apply the mitochondrial donation regulations in practice. It is therefore entirely appropriate, and indeed essential, that the HFEA was consulted on the wording of the draft regulations to ensure that they will work in regulatory practice. The HFEA was consulted on the draft regulations that were published for public consultation in February 2014 and on the revised regulations that took account of the comment received in that consultation that were debated in both Houses of Parliament.<\/p>
<\/p>
<\/p>
<\/p>
The Human Fertilisation and Embryology (Mitochondrial Donation) Regulations 2015 were approved by the House of Commons on 3 February 2015 and by the House of Lords on 24 February 2015. They come in to force on 29 October 2015. It would have been inappropriate for the HFEA to finalise its proposals for the regulation, monitoring and reporting of mitochondrial donation treatment cycles in advance of Parliament\u2019s decision.<\/p>
<\/p>
<\/p>
<\/p>
Outline plans of the HFEA\u2019s proposals in this area were discussed at the Authority\u2019s 11 March 2015 meeting, which was open to the public to observe. The HFEA has advised that there is no delay. The minutes will be available on the HFEA website in due course.<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"} } , "answeringMemberPrinted" : {"_value" : "Earl Howe"} , "dateOfAnswer" : {"_value" : "2015-03-24", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2015-03-24T15:01:26.86Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2015-03-11", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "IVF"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty\u2019s Government, further to the remarks by Earl Howe on 24 February (HL Deb, col 1622) and the Written Answer by Earl Howe on 9 March (HL5132), for how many years the Human Fertilisation and Embryology Authority (HFEA) has been advising them on the drafting of regulations for proposed interventions for mitochondrial disease; what are the reasons for the current delay in the HFEA announcing its proposals for the regulation, monitoring and reporting of mitochondrial donation treatment cycles; whether it is still their view that \"further delay would not be doing the right the thing for families who desperately want to have the choice to access these new techniques\"; if so, how delays due to the HFEA have already been explained to such families; and whether they will be able to announce publication of the HFEA\u2019s proposals for regulation, monitoring and reporting in advance of the next General Election.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/738", "label" : {"_value" : "Biography information for Lord Alton of Liverpool"} } , "tablingMemberPrinted" : [{"_value" : "Lord Alton of Liverpool"} ], "uin" : "HL5620"} , {"_about" : "http://data.parliament.uk/resources/226827", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/226827/answer", "answerText" : {"_value" : "
The Human Fertilisation and Embryology Authority (HFEA) has advised that it uses standard definitions for miscarriages and stillbirths: miscarriage is a pregnancy loss up to 24 weeks gestation and a stillbirth after 24 weeks completed gestation.<\/p>
<\/p>
<\/p>
<\/p>
\u2018Abnormalities\u2019 are considered depending on the specific details and circumstances of the case.<\/p>
<\/p>
<\/strong><\/p> <\/p> As stated in my written answer of 10 February 2015 (HL4443<\/a>), I have nothing further to add to the answers given previously on the subject of the published abstract of the Zhang research group.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"}
}
, "answeringMemberPrinted" : {"_value" : "Earl Howe"}
, "dateOfAnswer" : {"_value" : "2015-03-25", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-03-25T15:57:52.637Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-03-11", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "IVF"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty\u2019s Government, further to the Written Answers by Earl Howe on 10 February (HL4443) and 9 March (HL5132), to what extent miscarriages and stillbirths are considered by the HFEA to be abnormalities; and when they will place in the Library of the House a full copy of the correspondence between the member of the HFEA\u2019s Expert Panel and the Zhang research group.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/738", "label" : {"_value" : "Biography information for Lord Alton of Liverpool"}
}
, "tablingMemberPrinted" : [{"_value" : "Lord Alton of Liverpool"}
], "uin" : "HL5621"}
, {"_about" : "http://data.parliament.uk/resources/226828", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/226828/answer", "answerText" : {"_value" : " The Human Fertilisation and Embryology Authority (HFEA) has informed us that it has been advised by the Medicines and Healthcare products Regulatory Agency (MHRA) that medical devices manufactured and used within the same healthcare institution without having been transferred to a different legal entity do not come within the scope of the Medical Devices Directives referred to, and do not therefore need to be CE marked.<\/p> <\/p> <\/p> <\/p> I have nothing further to add to my previous answer of 20 February 2015, HL4711<\/a>, regarding HFEA licencing conditions and guidance in relation to the use of CE marked and non-CE marked products.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"}
}
, "answeringMemberPrinted" : {"_value" : "Earl Howe"}
, "dateOfAnswer" : {"_value" : "2015-03-24", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-03-24T15:02:54.863Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-03-11", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "IVF"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty\u2019s Government to what extent Council Directive 93/42 EEC of 14 June 1993 concerning medical devices and Directive 98/79 EEC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices applies to items such as IVF laboratory equipment or reagents where there is no intention to place such items on the market; how it is possible for a fertility clinic to obtain CE marking for items that they do not intend to place on the market for the purposes of HFEA licence condition T30; and what consideration is given to the quality, safety and efficacy of in-house products that conform to the highest clinical standards and which demonstrably exceed those of marketed equivalents.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/738", "label" : {"_value" : "Biography information for Lord Alton of Liverpool"}
}
, "tablingMemberPrinted" : [{"_value" : "Lord Alton of Liverpool"}
], "uin" : "HL5622"}
, {"_about" : "http://data.parliament.uk/resources/225735", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/225735/answer", "answerText" : {"_value" : " The Human Fertilisation and Embryology Authority (HFEA) has advised that it has an information sharing agreement with the Medicines and Healthcare products Regulatory Agency (MHRA) so that the two organisations can better regulate the IVF sector. This can be found on the Authority\u2019s website at:<\/p> <\/p> <\/p> <\/p>